Article

Indications and pivotal trials of the FDA approved small-molecular kinase inhibitors in cancer therapies with and without biomarker of cancer driver gene

2022-03-15

Abstract excerpt

<h4>Background: </h4> Cancer precision medicine with biomarker of cancer driver gene (CDG) has been achieved by many small-molecular kinase inhibitors (SMKIs) approved by the US Food and Drug Administration (FDA). We characterized their indications and pivotal trials with and without CDG biomarker. <h4>Methods: </h4>: Publicly available FDA documents were collected for all SMKI cancer drugs approved between Januar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 37dbca10-5349-5a86-acd0-ebbe88b73c9b
DOI: 10.21203/rs.3.rs-1443724/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Indications and pivotal trials of the FDA approved small-molecular kinase inhibitors in cancer therapies with and without biomarker of cancer driver geneDOI 10.21203/rs.3.rs-1443724/v1Read

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity Read

Cancer driver genes and opportunities for precision oncology revealed by whole genome sequencing 10,478 cancersSemantic proximity Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

The Precision Medicine: Advancement and Transformation in Cancer TreatmentSemantic proximity Read

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Semantic proximity Read

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkersSemantic proximity Read

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read

Trend Analysis of Regulatory Approval Pathways and Major Shifts in Pivotal Clinical Trial Designs for Antineoplastic Drugs Approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) From 2004 to 2019.Semantic proximity Read

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read